Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nagoya University Pancreatic Tumor Board Trial 07 (NUPAT-07)
jRCTs041200028Recruiting
- Sponsor
- Johnson & Johnson
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of paclitaxel and gemcitabine in pancreatic cancer (PC) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: R0 resection rate. Started Jul 2020; status: recruiting.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs041200028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200028.